Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Foghorn Therapeutics (Nasdaq: FHTX) announced that management will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, FL, December 2-4, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX) announced that management will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, FL, December 2-4, 2025.
The company said a Fireside Chat with Adrian Gottschalk, president and CEO, is scheduled for Thursday, December 4, 2025 at 9:10 a.m. EST. Management will also hold one-on-one meetings. A webcast of the presentation will be available under Events & Presentations on the company website and will be accessible for 30 days.
Details
News Market Reaction – FHTX
On Nov 25, the day this news came out, FHTX closed 3.51% above the previous close.
Data tracked by StockTitan Argus for the Nov 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Fireside Chat Date and Time: Thursday December 4, 2025, at 9:10 a.m. EST
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings
A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. khellsvik@foghorntx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.